¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.
°íÁÖÆÄ ÀýÁ¦ ±â±â ½ÃÀå ¼ºÀå ¹× µ¿Çâ :
°íÁÖÆÄ ÀýÁ¦ ±â±â(Radiofrequency Ablation Devices) ¼¼°è ½ÃÀå ±Ô¸ð´Â ¿¹Ãø ±â°£ µ¿¾È CAGR 11.9%·Î ¼ºÀåÀ» Áö¼ÓÇϰí, 2030³â±îÁö 105¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
ÃÖ¼Ò Ä§½À ¼ö¼ú¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡, ³ëÀÎ Àα¸ Áõ°¡, ´õ ³ªÀº Áúº´ Ä¡·á¸¦ À§ÇÑ °Ç° °ü¸® ÁöÃâ Áõ°¡°¡ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¹Ì±¹ ¼ºÇü¿Ü°úÇÐȸ(American Society of Plastic Surgeons)¿¡ µû¸£¸é 2015³â ¸»±îÁö ¹Ì±¹¿¡¼´Â 1,590¸¸ °ÇÀÇ ÃÖ¼Ò Ä§½À ¹Ì¿ë ¼ö¼úÀÌ ÀÌ·ç¾îÁ³½À´Ï´Ù. ¹Ì±¹ Áúº´ ¿¹¹æ °ü¸® ¼¾ÅÍ(Centers for Disease Control and Prevention : CDC)¿¡ µû¸£¸é, ¹Ì±¹ ¹× EU ±¹°¡¿¡¼´Â ¸Å³â 600¸¸ °Ç ÀÌ»óÀÇ º¹°°æ ¼ö¼úÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù.
°íÁÖÆÄ ÀýÁ¦¹ýÀº ÇöÀç ½É¹æ ºó¸Æ, ½É¹æ ¼¼µ¿ ¹× ±âŸ °ü»ó µ¿¸Æ ÁúȯÀ» ¾Î°íÀִ ȯÀÚÀÇ °ü¸®¿¡ Á¶±â¿¡ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. À̰ÍÀÌ ½ÃÀå ¼ºÀåÀ» ¹Ð¾î ¿Ã¸± °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹Ì±¹ ½ÉÀ庴ÇÐȸ(American College of Cardiology Foundation)¿¡ µû¸£¸é ¹Ì±¹¿¡¼´Â °ü»óµ¿¸Æ¼º ½ÉÀåÁúȯÀÌ »çÀÎÀÇ Åé(43.8%)¿¡¼ ³úÁ¹Áß(16.8%), ½ÉºÎÀü(9.0%), °íÇ÷¾Ð(9.4%), ±âŸ CVD(17.9%)°¡ ÀÌ¿¡ À̾îÁý´Ï´Ù. 2035³â±îÁö CVDÀÇ ÃÑ ºñ¿ëÀº 1Á¶ 1,000¾ï ´Þ·¯¿¡ À̸£°í, ¹Ì±¹ ¼ºÀÎÀÇ 45.1%(1¾ï 3,000¸¸ ¸í)°¡ º´¿¡ °É¸± °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
°íÁÖÆÄ ÀýÁ¦¹ýÀº ¸ñ ÅëÁõ, ¿äÅë, °üÀý¿°, °ñ¹Ý ¹× ¸»ÃÊ ½Å°æ ÅëÁõÀ» ÁÙÀÌ´Â µ¥¿¡µµ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. WebMD LLC.¿¡ µû¸£¸é RFA´Â ÅëÁõÀ» ´À³¢´Â ȯÀÚÀÇ 70% À̻󿡼 È¿°úÀûÀÓÀÌ ÀÔÁõµÇ¾ú½À´Ï´Ù. RFA·Î ÀÎÇÑ ÅëÁõ °¨¼Ò´Â 6°³¿ù¿¡¼ 12°³¿ù ¶Ç´Â 1³â µ¿¾È Áö¼ÓµÉ ¼ö ÀÖ½À´Ï´Ù.
°íÁÖÆÄ ÀýÁ¦ ±â±â ½ÃÀå º¸°í¼ ¹× ÇÏÀ̶óÀÌÆ®
- ÀÌȯÀ²À̳ª »ç¸Á·üÀÇ ÀúÇÏ, ¿Ü·¡¿¡¼ Ä¡·á°¡ °¡´ÉÇϱ⠶§¹®¿¡ 2022³â¿¡´Â ÀÏȸ¿ë ±â±â°¡ ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¿¹¸¦ µé¾î, Radiopaque RF ij´¼¶ó(Halyard Worldwide, Inc)´Â Á¤È®ÇÑ À§Ä¡°áÁ¤À» À§ÇØ Åõ½ÃÇÏ¿¡¼ ½Ã°¢È°¡ °³¼±µÇ¾î Ç¥ÀûÀ» Á¼Èù Ä¡·á°¡ °¡´ÉÇÕ´Ï´Ù.
- ½ÉÀ庴Çаú ½ÉÀåÁ¶À²°ü¸®´Â Áúº´ÀÇ È®»ê, ÀÎÁöµµÀÇ Çâ»ó, ÃÖ¼Ò Ä§½À ¼ö¼úÀÇ Ã¤Åÿ¡ ÀÇÇØ ¿¹Ãø±â°£ Áß¿¡ °¡Àå ±Þ¼ºÀåÇÏ´Â ºÐ¾ß·Î ¿¹»óµË´Ï´Ù.
- ºÏ¹Ì´Â ¸·´ëÇÑ ÀÇ·áºñ, ½ÉÀå Áúȯ°ú ¾Ï ¹ß»ý·ü, ÅëÁõ¿¡ ½Ã´Þ¸®´Â ȯÀÚÀÇ ¸¹À½À¸·Î ¿¹Ãø ±â°£ µ¿¾È¿¡µµ °íÁÖÆÄ ÀýÁ¦ ±â±â ½ÃÀåÀ» ¼±µµÇÏ´Â °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
- ¾Æ½Ã¾Æ ÅÂÆò¾çÀº ¾Ï Ä¡·á¸¦ À§ÇÑ ÃÖ¼Ò Ä§½À ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ´Â °Í, ±âÁ¸ÀÇ ¼ö¼ú ¼ö¼úº¸´Ù ¾îºí·¹À̼ǹýÀÌ ¿ì¼öÇÏ´Ù´Â ÀνÄÀÌ ³ô¾ÆÁö°í Àֱ⠶§¹®¿¡ ÇâÈÄ 10³â°£ Å« ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý ¹× ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå °íÁÖÆÄ ÀýÁ¦ ±â±â ½ÃÀå º¯¼ö, µ¿Çâ ¹× ¹üÀ§
- ½ÃÀå °èÅë Àü¸Á
- »óÀ§ ½ÃÀå Àü¸Á
- °ü·Ã/ºÎ¼öÀûÀÎ ½ÃÀå Àü¸Á
- º¸±Þ ¹× ¼ºÀå Àü¸Á ¸ÅÇÎ
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø ¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦ ¿äÀÎ ºÐ¼®
- °íÁÖÆÄ ÀýÁ¦ ±â±â ½ÃÀå ºÐ¼® µµ±¸
- »ê¾÷ ºÐ¼®-Porter's Five Forces ºÐ¼®
- PESTEL ºÐ¼®
Á¦4Àå °íÁÖÆÄ ÀýÁ¦ ±â±â : ±¸¼º ¿ä¼Òº° ÃßÁ¤¡¤µ¿Ç⠺м®
- °íÁÖÆÄ ÀýÁ¦ ±â±â ½ÃÀå : Áß¿ä Æ÷ÀÎÆ®
- °íÁÖÆÄ ÀýÁ¦ ±â±â ½ÃÀå : µ¿Çâ ¹× ½ÃÀå Á¡À¯À² ºÐ¼®(2022³â, 2030³â)
- ÀÏȸ¿ë ±â±â
- ÀÏȸ¿ë ±â±â ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø(2018-2030³â)
- ÀÚº» ¼³ºñ
- ÀÚº» ¼³ºñ ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø(2018-2030³â)
- Àç»ç¿ë °¡´ÉÇÑ ±â±â
- Àç»ç¿ë °¡´ÉÇÑ ±â±â ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø(2018-2030³â)
Á¦5Àå °íÁÖÆÄ ÀýÁ¦ ±â±â : ¿ëµµº° ÃßÁ¤¡¤µ¿Ç⠺м®
- °íÁÖÆÄ ÀýÁ¦ ±â±â ½ÃÀå : Áß¿ä Æ÷ÀÎÆ®
- °íÁÖÆÄ ÀýÁ¦ ±â±â ½ÃÀå : µ¿Çâ ¹× ½ÃÀå Á¡À¯À² ºÐ¼®(2022³â, 2030³â)
- Á¾¾ç¿Ü°ú
- ½ÉÀ庴ÇÐ ¹× ½ÉÀå ¹Úµ¿ °ü¸®
- ¹Ì¿ëÇÐ
- ºÎÀΰú
- ÅëÁõ °ü¸®
Á¦6Àå °íÁÖÆÄ ÀýÁ¦ ±â±â : ÃÖÁ¾ ¿ëµµº° ÃßÁ¤¡¤µ¿Ç⠺м®
- °íÁÖÆÄ ÀýÁ¦ ±â±â ½ÃÀå : Áß¿ä Æ÷ÀÎÆ®
- °íÁÖÆÄ ÀýÁ¦ ±â±â ½ÃÀå : µ¿Çâ ¹× ½ÃÀå Á¡À¯À² ºÐ¼®(2022³â, 2030³â)
- º´¿ø
- º´¿ø ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø(2018-2030³â)
- ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
- ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø(2018-2030³â)
- Á¶»ç
- Á¶»ç ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø(2018-2030³â)
Á¦7Àå °íÁÖÆÄ ÀýÁ¦ ±â±â ½ÃÀå : Áö¿ªº° ÃßÁ¤¡¤µ¿Ç⠺м®
- Áö¿ªº° Àü¸Á
- Áö¿ªº° °íÁÖÆÄ ÀýÁ¦ ±â±â ½ÃÀå : Áß¿ä Æ÷ÀÎÆ®
- ºÏ¹Ì
- À¯·´
- ¾Æ½Ã¾Æ ÅÂÆò¾ç
- ³²¹Ì
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦8Àå °æÀï ±¸µµ
- ÁÖ¿ä ½ÃÀå ÁøÃâ ±â¾÷¿¡ ÀÇÇÑ ÃÖ±Ù µ¿Çâ ¹× ¿µÇ⠺м®
- ½ÃÀå ÁøÃâ ±â¾÷ ºÐ·ù
- Boston Scientific Corporation
- Medtronic
- Stryker
- Abbott.
- Smith Nephew.
- Johnson & Johnson Services, Inc.
- AngioDynamics
LYJ 23.10.30
Radiofrequency Ablation Devices Market Growth & Trends:
The global radiofrequency ablation devices market size is expected to reach USD 10.5 billion by 2030, registering a CAGR of 11.9% during the forecast period, according to a new report by Grand View Research, Inc.. Increasing preference for minimally invasive surgeries, growing geriatric population, and rise in healthcare spending for better disease treatment are expected to propel the growth.
According to the American Society of Plastic Surgeons, by the end of 2015, 15.9 million minimally invasive cosmetic surgeries were performed in U.S. According to the Centers for Disease Control and Prevention (CDC), more than six million laparoscopic procedures are performed across the U.S. and EU countries every year.
Radiofrequency ablation is now used early in the management of patients suffering from atrial tachycardia or atrial fibrillation or other kinds of coronary disease. This factor is anticipated to boost the market growth. According to the American College of Cardiology Foundation, coronary heart disease is the leading cause of deaths (43.8%) in U.S., followed by stroke (16.8%), heart failure (9.0%), high BP (9.4%), and other CVDs (17.9%). By 2035, the total cost of CVD is expected to reach USD 1.1 trillion and is projected to affect 45.1% (130 million) adults in U.S.
Radiofrequency ablation can also be used to reduce neck pain, low-back pain, arthritis, and pelvic and peripheral nerve pain. According to WebMD LLC., RFA has been proven to be effective in more than 70% of the patients experiencing pain. Pain relief from RFA can last from six to 12 months or even a year.
Radiofrequency Ablation Devices Market Report Highlights:
- Disposable equipment held the largest market share in 2022 due to reduced morbidity and mortality and the ability of the equipment to provide treatment in an outpatient setting. For example, Radiopaque RF cannula (Halyard Worldwide, Inc) provides improved visualization under fluoroscopy for accurate positioning, resulting in a targeted treatment
- Cardiology and cardiac rhythm management is anticipated to be the fastest-growing segment during the forecast period due to disease prevalence, growing awareness, and adoption of minimally invasive operations.
- North America is anticipated to continue leading the radiofrequency ablation devices market during the forecast period due to high healthcare expenditure, incidence of cardiac disease and cancer, and the number of patients suffering from pain
- Asia Pacific is expected to witness significant growth over the next decade due to increasing demand for minimally invasive procedures to treat cancer and growing awareness regarding the benefits of ablation method over the conventional surgical procedures.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Component Type
- 1.1.2. Application
- 1.1.3. End use
- 1.1.4. Regional scope
- 1.1.5. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Component type outlook
- 2.2.2. Application outlook
- 2.2.3. End use outlook
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Radiofrequency Ablation Devices Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Market Dynamics
- 3.3.1. Market driver analysis
- 3.3.2. Market restraint analysis
- 3.4. Radiofrequency Ablation Devices Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's
- 3.4.1.1. Supplier power
- 3.4.1.2. Buyer power
- 3.4.1.3. Substitution threat
- 3.4.1.4. Threat of new entrant
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Technological landscape
- 3.4.2.3. Economic landscape
Chapter 4. Radiofrequency Ablation Devices: Component Type Estimates & Trend Analysis
- 4.1. Radiofrequency Ablation Devices Market: Key Takeaways
- 4.2. Radiofrequency Ablation Devices Market: Movement & Market Share Analysis, 2022 & 2030
- 4.3. Disposable Equipment
- 4.3.1. Disposable equipment market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4. Capital Equipment
- 4.4.1. Capital equipment market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.5. Reusable Equipment
- 4.5.1. Reusable equipment market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Radiofrequency Ablation Devices: Application Estimates & Trend Analysis
- 5.1. Radiofrequency Ablation Devices Market: Key Takeaways
- 5.2. Radiofrequency Ablation Devices Market: Movement & Market Share Analysis, 2022 & 2030
- 5.3. Surgical Oncology
- 5.3.1. Surgical oncology market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4. Cardiology & Cardiac Rhythm Management
- 5.4.1. Cardiology & cardiac rhythm management market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5. Cosmetology
- 5.5.1. Cosmetology market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.6. Gynaecology
- 5.6.1. Gynaecology market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.7. Pain Management
- 5.7.1. Pain management market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Radiofrequency Ablation Devices: End Use Estimates & Trend Analysis
- 6.1. Radiofrequency Ablation Devices Market: Key Takeaways
- 6.2. Radiofrequency Ablation Devices Market: Movement & Market Share Analysis, 2022 & 2030
- 6.3. Hospital
- 6.3.1. Hospital market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.4. Ambulatory Surgery Centers
- 6.4.1. Ambulatory surgery centers market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.5. Research Laboratories
- 6.5.1. Research laboratories market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Radiofrequency Ablation Devices Market: Regional Estimates & Trend Analysis
- 7.1. Regional Outlook
- 7.2. Radiofrequency Ablation Devices Market by Region: Key Takeaways
- 7.3. North America
- 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.3.2. U.S.
- 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.3.3. Canada
- 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4. Europe
- 7.4.1. UK
- 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.2. Germany
- 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.3. France
- 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.4. Italy
- 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.5. Spain
- 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.6. Denmark
- 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.7. Sweden
- 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.8. Norway
- 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5. Asia Pacific
- 7.5.1. Japan
- 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.2. China
- 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.3. India
- 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.4. Australia
- 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.5. Thailand
- 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.6. South Korea
- 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.6. Latin America
- 7.6.1. Brazil
- 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.6.2. Mexico
- 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.6.3. Argentina
- 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7. MEA
- 7.7.1. South Africa
- 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.2. Arabia
- 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.3. UAE
- 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.4. Kuwait
- 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Market Participant Categorization
- 8.2.1. Boston Scientific Corporation
- 8.2.1.1. Company overview
- 8.2.1.2. Financial performance
- 8.2.1.3. Product benchmarking
- 8.2.1.4. Strategic initiatives
- 8.2.2. Medtronic
- 8.2.2.1. Company overview
- 8.2.2.2. Financial performance
- 8.2.2.3. Product benchmarking
- 8.2.2.4. Strategic initiatives
- 8.2.3. Stryker
- 8.2.3.1. Company overview
- 8.2.3.2. Financial performance
- 8.2.3.3. Product benchmarking
- 8.2.3.4. Strategic initiatives
- 8.2.4. Abbott.
- 8.2.4.1. Company overview
- 8.2.4.2. Financial performance
- 8.2.4.3. Product benchmarking
- 8.2.4.4. Strategic initiatives
- 8.2.5. Smith+Nephew.
- 8.2.5.1. Company overview
- 8.2.5.2. Financial performance
- 8.2.5.3. Product benchmarking
- 8.2.5.4. Strategic initiatives
- 8.2.6. Johnson & Johnson Services, Inc.
- 8.2.6.1. Company overview
- 8.2.6.2. Financial performance
- 8.2.6.3. Product benchmarking
- 8.2.6.4. Strategic initiatives
- 8.2.7. AngioDynamics
- 8.2.7.1. Company overview
- 8.2.7.2. Financial performance
- 8.2.7.3. Product benchmarking
- 8.2.7.4. Strategic initiatives